{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T11:23:50Z","timestamp":1761218630113,"version":"3.41.2"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T00:00:00Z","timestamp":1702339200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:p>Malignant tumors of the biliary tract exhibit a high degree of malignancy and heterogeneity with a poor overall prognosis. Immunotherapy has limited benefits for patients with cholangiocarcinoma. Radiation therapy can change the tumor microenvironment, but its effect heavily depends on radiation dose and fraction. We report a case of advanced intrahepatic cholangiocarcinoma in a 43-year-old male patient, with a huge liver mass of 16.5\u00a0cm in diameter, with bone and liver metastases at the first diagnosis. First-line treatment with chemotherapy and PD1 inhibitor was sustained only for 8 months. In second-line treatment, radiotherapy was administered, with 5 Gy in 5 fractions administered to the entire tumor area and 25 Gy in 5 fractions to the solid lesions of the tumor. After the completion of radiotherapy, programmed cell death 1 inhibitor combined with tyrosine kinase inhibitor was maintained. The patient achieved a progression-free-survival time of 12 months and an overall survival time of 25 months. The success of our case suggests that mixed low- and high-dose radiation can significantly improve tumor control and survival time. In clinical practice, based on the characteristics of the tumor and existing treatment options, the rational combination of existing treatment regimens can improve the prognosis of cholangiocarcinoma.<\/jats:p>","DOI":"10.3389\/fimmu.2023.1273962","type":"journal-article","created":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T15:00:10Z","timestamp":1702393210000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Case Report: A novel mixture of dose-fractioned radiation and immunotherapy for treatment of cholangiocarcinoma"],"prefix":"10.3389","volume":"14","author":[{"given":"Ningyu","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linfang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jun","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Cao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangping","family":"Mei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Yao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yong","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,12,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.3390\/cancers12082039","article-title":"Targeted therapies in advanced biliary tract cancer: an evolving paradigm","volume":"12","author":"Chakrabarti","year":"2020","journal-title":"Cancers (Basel)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1111\/liv.14095","article-title":"Cholangiocarcinoma: Epidemiology and risk factors","volume":"39","author":"Khan","year":"2019","journal-title":"Liver Int"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.21037\/hbsn.2017.01.02","article-title":"Epidemiology and risk factors: intrahepatic cholangiocarcinoma","volume":"6","author":"Gupta","year":"2017","journal-title":"Hepatobiliary Surg Nutr"},{"key":"B4","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1159\/000453013","article-title":"Epidemiology and risk factors of cholangiocarcinoma","volume":"32","author":"Kirstein","year":"2016","journal-title":"Visc Med"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.5604\/01.3001.0010.0293","article-title":"Prevalence, risk factors, and survival of patients with intrahepatic cholangiocarcinoma","volume":"16","author":"Chinchilla-Lopez","year":"2017","journal-title":"Ann Hepatol"},{"key":"B6","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.cgh.2012.09.009","article-title":"Classification, diagnosis, and management of cholangiocarcinoma","volume":"11","author":"Razumilava","year":"2013","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908721","article-title":"Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer","volume":"362","author":"Valle","year":"2010","journal-title":"N Engl J Med"},{"key":"B8","doi-asserted-by":"publisher","first-page":"820","DOI":"10.3390\/ijms23020820","article-title":"Immunotherapy for biliary tract cancer in the era of precision medicine: current knowledge and future perspectives","volume":"23","author":"Ciardiello","year":"2022","journal-title":"Int J Mol Sci"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.868034","article-title":"Progress in radiotherapy for cholangiocarcinoma","volume":"12","author":"Wang","year":"2022","journal-title":"Front Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2020-002038","article-title":"Radiation dose and fraction in immunotherapy: one-size regimen does not fit all settings, so how does one choose","volume":"9","author":"Demaria","year":"2021","journal-title":"J Immunother Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-13-0141","article-title":"Harnessing the potential of radiation-induced immune modulation for cancer therapy","volume":"1","author":"Ahmed","year":"2013","journal-title":"Cancer Immunol Res"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-0265","article-title":"Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody","volume":"15","author":"Dewan","year":"2009","journal-title":"Clin Cancer Res"},{"key":"B13","doi-asserted-by":"publisher","first-page":"3212","DOI":"10.3390\/ijms20133212","article-title":"Tumor microenvironment as A \"Game changer\" in cancer radiotherapy","volume":"20","author":"Jarosz-Biej","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41575-020-0310-z","article-title":"Cholangiocarcinoma 2020: the next horizon in mechanisms and management","volume":"17","author":"Banales","year":"2020","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.832047","article-title":"The role of histone post-translational modifications in merkel cell carcinoma","volume":"12","author":"Mazziotta","year":"2022","journal-title":"Front Oncol"},{"key":"B16","doi-asserted-by":"publisher","first-page":"223","DOI":"10.3390\/jcm9010223","article-title":"Anti-PD-1 and novel combinations in the treatment of melanoma-an update","volume":"9","author":"Gellrich","year":"2020","journal-title":"J Clin Med"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103375","article-title":"Tumor-associated macrophages in cholangiocarcinoma: complex interplay and potential therapeutic target","volume":"67","author":"Zhou","year":"2021","journal-title":"EBioMedicine"},{"key":"B18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/liv.14093","article-title":"Anatomical, histomorphological and molecular classification of cholangiocarcinoma","volume":"39","author":"Kendall","year":"2019","journal-title":"Liver Int"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1002\/hep.31092","article-title":"Identification of four immune subtypes characterized by distinct composition and functions of tumor microenvironment in intrahepatic cholangiocarcinoma","volume":"72","author":"Job","year":"2020","journal-title":"Hepatology"},{"key":"B20","doi-asserted-by":"publisher","first-page":"101270","DOI":"10.1016\/j.smim.2019.03.002","article-title":"Innate lymphoid cells as regulators of the tumor microenvironment","volume":"41","author":"Tugues","year":"2019","journal-title":"Semin Immunol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2022.04.003","article-title":"Radiation therapy-induced remodeling of the tumor immune microenvironment","volume":"86","author":"Charpentier","year":"2022","journal-title":"Semin Cancer Biol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2018.06.001","article-title":"Antiangiogenic therapy: Markers of response, \"normalization\" and resistance","volume":"128","author":"El Alaoui-Lasmaili","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2018.00367","article-title":"The tumor vascular endothelium as decision maker in cancer therapy","volume":"8","author":"Klein","year":"2018","journal-title":"Front Oncol"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.01625","article-title":"Hypoxic stress-induced tumor and immune plasticity, suppression, and impact on tumor heterogeneity","volume":"8","author":"Terry","year":"2017","journal-title":"Front Immunol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2824","article-title":"Ablative tumor radiation can change the tumor immune cell microenvironment to induce durable complete remissions","volume":"21","author":"Filatenkov","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-2581","article-title":"The reciprocity between radiotherapy and cancer immunotherapy","volume":"25","author":"Wang","year":"2019","journal-title":"Clin Cancer Res"},{"key":"B27","doi-asserted-by":"publisher","first-page":"791","DOI":"10.1586\/era.10.217","article-title":"Low-dose radiation therapy of cancer: role of immune enhancement","volume":"11","author":"Farooque","year":"2011","journal-title":"Expert Rev Anticancer Ther"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12572","article-title":"Immunomodulation by ionizing radiation-impact for design of radio-immunotherapies and for treatment of inflammatory diseases","volume":"280","author":"Frey","year":"2017","journal-title":"Immunol Rev"},{"key":"B29","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-18-3518","article-title":"Postablation Modulation after Single High-Dose Radiation Therapy Improves Tumor Control via Enhanced Immunomodulation","volume":"26","author":"Savage","year":"2020","journal-title":"Clin Cancer Res"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1273962\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,12,12]],"date-time":"2023-12-12T15:00:13Z","timestamp":1702393213000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2023.1273962\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,12]]},"references-count":29,"alternative-id":["10.3389\/fimmu.2023.1273962"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2023.1273962","relation":{},"ISSN":["1664-3224"],"issn-type":[{"type":"electronic","value":"1664-3224"}],"subject":[],"published":{"date-parts":[[2023,12,12]]},"article-number":"1273962"}}